Corporate Presentation Leader in AAV Gene Therapy September 6, 2019 Forward-looking statements This presentation includes "forward-looking statements," within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements express a belief, expectation or intention and are generally accompanied by words that convey projected future events or outcomes such as "believe," "may," "will," "estimate," "continue," "anticipat ...

Regenxbio, Inc. (NASDAQ:RGNX) Q2 2019 Earnings Conference Call August 7, 2019 4:30 PM ET Company Participants Sara Garon Berl - Vice President of Law and Policy for REGENXBIO Kenneth Mills – Chief Executive Offier, President and Director Vittal Vasista - Chief Financial Officer Steve Pakola - Chief Medical Officer Conference Call Participants Mani Foroohar - SVB Leerink Gena Wang - Barclays Operator Good afternoon and welcome to the REGENXBIO Second Quarter 2019 Earnings Conference Call. At this time, all p ...

Table of Contents ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) For the quarterly period ended June 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___ to ___ Commission File Number 001-37553 REGENXBIO Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 47-1851754 (State ...

Regenxbio, Inc. (NASDAQ:RGNX) Q1 2019 Earnings Conference Call May 7, 2019 4:30 PM ET Company Participants Patrick Christmas - SVP & General Counsel Kenneth Mills - CEO, President & Director Steve Pakola - Chief Medical Officer Vittal Vasista - CFO Conference Call Participants Matthew Harrison - Morgan Stanley Gena Wang - Barclays Bank Mani Foroohar - SVB Leerink Joshua Schimmer - Evercore ISI Operator Good afternoon and welcome to the REGENXBIO First Quarter 2019 Earnings Conference Call. At this time, all ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___ to ___ Commission File Number 001-37553 REGENXBIO Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 47-1851754 (State ...

REGENXBIO (NASDAQ:RGNX) Q4 2018 Results Earnings Conference Call February 27, 2019 4:30 AM ET Company Participants Patrick Christmas - Senior Vice President, General Counsel Ken Mills - President, Chief Executive Officer Vit Vasista - Senior Vice President, Chief Financial Officer Conference Call Participants Xiaobin Gao - Barclays Gbola Amusa - Chardan Reni Benjamin - Raymond James Mani Foroohar - Leerink Operator Good afternoon and welcome to the REGENXBIO fourth quarter and full year 2018 earnings confer ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37553 REGENXBIO Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorp ...